JP2019537582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019537582A5 JP2019537582A5 JP2019522710A JP2019522710A JP2019537582A5 JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5 JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019522710 A JP2019522710 A JP 2019522710A JP 2019537582 A5 JP2019537582 A5 JP 2019537582A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- hearing loss
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 206010011878 Deafness Diseases 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 11
- 230000010370 hearing loss Effects 0.000 claims 11
- 231100000888 hearing loss Toxicity 0.000 claims 11
- 208000016354 hearing loss disease Diseases 0.000 claims 11
- SRHWORQGHZESJE-UHFFFAOYSA-N N-[1-(4,6-disulfonylcyclohex-2-en-1-yl)-2,2-dimethylpropylidene]hydroxylamine Chemical compound CC(C)(C)C(=NO)C1C=CC(CC1=S(=O)=O)=S(=O)=O SRHWORQGHZESJE-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 3
- 206010063602 Exposure to noise Diseases 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 210000003030 auditory receptor cell Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 238000004880 explosion Methods 0.000 claims 2
- 231100000573 exposure to toxins Toxicity 0.000 claims 2
- 210000004307 hair cells vestibular Anatomy 0.000 claims 2
- 230000014511 neuron projection development Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000000946 synaptic effect Effects 0.000 claims 2
- 230000001720 vestibular Effects 0.000 claims 2
- JKRODHBGNBKZLE-YUMQZZPRSA-N (2s)-2-amino-5-[[(2r)-1-[(2-ethoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CCOC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O JKRODHBGNBKZLE-YUMQZZPRSA-N 0.000 claims 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims 1
- 229930182818 D-methionine Natural products 0.000 claims 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims 1
- 206010020559 Hyperacusis Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 108700024319 S-ethyl glutathione Proteins 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950010033 ebselen Drugs 0.000 claims 1
- 239000002360 explosive Substances 0.000 claims 1
- 210000000067 inner hair cell Anatomy 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 210000002241 neurite Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 210000002985 organ of corti Anatomy 0.000 claims 1
- 208000009800 presbycusis Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 230000007470 synaptic degeneration Effects 0.000 claims 1
- 102000013498 tau Proteins Human genes 0.000 claims 1
- 108010026424 tau Proteins Proteins 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415101P | 2016-10-31 | 2016-10-31 | |
| US62/415,101 | 2016-10-31 | ||
| US201762488740P | 2017-04-22 | 2017-04-22 | |
| US62/488,740 | 2017-04-22 | ||
| US201762510596P | 2017-05-24 | 2017-05-24 | |
| US62/510,596 | 2017-05-24 | ||
| US201762550345P | 2017-08-25 | 2017-08-25 | |
| US62/550,345 | 2017-08-25 | ||
| PCT/US2017/058834 WO2018081614A1 (en) | 2016-10-31 | 2017-10-27 | Methods for enhancing synaptogenesis and neuritogenesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019537582A JP2019537582A (ja) | 2019-12-26 |
| JP2019537582A5 true JP2019537582A5 (enExample) | 2020-12-03 |
Family
ID=62020809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522710A Pending JP2019537582A (ja) | 2016-10-31 | 2017-10-27 | シナプス形成および神経突起形成を増強するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10576125B2 (enExample) |
| EP (1) | EP3532042A4 (enExample) |
| JP (1) | JP2019537582A (enExample) |
| CN (1) | CN110248650A (enExample) |
| WO (1) | WO2018081614A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020036656A2 (en) | 2018-04-27 | 2020-02-20 | The Regents Of The University Of California | Inhibition of lipofuscin aggregation by molecular tweezers |
| US12076332B2 (en) | 2018-04-27 | 2024-09-03 | The Regents Of The University Of California | Treatment of lysosomal storage disorders |
| US20210137861A1 (en) * | 2018-05-03 | 2021-05-13 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
| WO2020056056A1 (en) | 2018-09-12 | 2020-03-19 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
| CN113811358A (zh) * | 2019-03-26 | 2021-12-17 | 通尼克斯制药控股有限公司 | S-(n,n-二乙基氨基甲酰基)谷胱甘肽的盐形式 |
| WO2020243478A1 (en) * | 2019-05-29 | 2020-12-03 | Massachusetts Eye And Ear Infirmary | Fibroblast growth factor 2 (fgf2) for treatment of human sensorineural hearing loss |
| CN112939823A (zh) * | 2019-12-10 | 2021-06-11 | 中国石油天然气股份有限公司 | 泥页岩抑制剂制备方法及抑制剂的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| US6064064A (en) * | 1996-03-01 | 2000-05-16 | Fire Sentry Corporation | Fire detector |
| KR100628847B1 (ko) | 1998-09-25 | 2006-09-29 | 세파론, 인코포레이티드 | 감각 유모 세포 및 와우 뉴런의 손상의 예방 또는 치료 방법 |
| MX2010011545A (es) * | 2008-04-21 | 2011-04-11 | Otonomy Inc | Formulaciones para tratar enfermedades y afecciones del oido. |
| TR201911199T4 (tr) * | 2009-03-27 | 2019-08-21 | Moleac Pte Ltd | Hücre büyümesini arttırmak için tedavi. |
| US10555915B2 (en) * | 2009-08-24 | 2020-02-11 | Hough Ear Institute | Methods for treating acute acoustic trauma |
| ES2893825T3 (es) * | 2011-02-04 | 2022-02-10 | Hough Ear Inst | Métodos de tratamiento de lesiones cerebrales |
| EP2872128B1 (en) | 2012-07-16 | 2020-02-19 | Cornell University | Nicotinamide riboside to treat hearing loss |
| CA2883896C (en) * | 2012-09-07 | 2023-03-07 | Massachusetts Eye & Ear Infirmary | Treating hearing loss |
| US9718805B2 (en) * | 2013-06-04 | 2017-08-01 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
-
2017
- 2017-10-27 WO PCT/US2017/058834 patent/WO2018081614A1/en not_active Ceased
- 2017-10-27 CN CN201780078374.7A patent/CN110248650A/zh active Pending
- 2017-10-27 EP EP17866191.4A patent/EP3532042A4/en active Pending
- 2017-10-27 JP JP2019522710A patent/JP2019537582A/ja active Pending
- 2017-10-27 US US15/796,522 patent/US10576125B2/en active Active
-
2020
- 2020-01-30 US US16/777,750 patent/US20200164021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019537582A5 (enExample) | ||
| US12336974B2 (en) | Methods and compositions for preventing and treating auditory dysfunctions | |
| JP2014511374A5 (enExample) | ||
| JP2007513079A5 (enExample) | ||
| RU2010150863A (ru) | Фармацевтическая композиция для лечения ушных заболеваний | |
| JP2013521231A5 (enExample) | ||
| KR20130099926A (ko) | 염증성 눈질환의 치료/예방용 화합물 | |
| JP2015522630A5 (enExample) | ||
| JP2016504389A5 (enExample) | ||
| JP2019537582A (ja) | シナプス形成および神経突起形成を増強するための方法 | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| EP3174543B1 (fr) | Dérivés de stérols pour le traitement de la perte auditive neurosensorielle et composition correspondante | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2018512451A5 (enExample) | ||
| US20220401420A1 (en) | Combination therapy having antioxydant properties | |
| CN117919232B (zh) | 吲哚丙酸在治疗肝硬化以及免疫性肝损伤的应用 | |
| CN104435465B (zh) | 一种治疗帕金森病的中药组合物 | |
| WO2023079954A1 (ja) | 内耳性難聴の抑制又は予防のためのエルゴチオネインを含む組成物 | |
| Ikezu et al. | P2RX7 regulates tauopathy progression via tau and mitochondria loading in extracellular vesicles | |
| JPWO2019213245A5 (enExample) | ||
| CN118787626A (zh) | 一种d-丝氨酸化合物在制备神经调节剂和治疗脑功能障碍药物中的应用 | |
| CN116600798A (zh) | 三苯甲酸甘油酯和苯丁酸甘油酯的给予用于治疗神经退行性疾病和尿素循环障碍 | |
| RU2640133C1 (ru) | Применение пептида thr-lys-pro-arg-pro-gly-pro (селанк) для профилактики и лечения токсического гепатита | |
| JP2010540661A5 (enExample) | ||
| US9763992B2 (en) | Treatment of noise induced hearing loss |